Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy auction to purchase 23andMe for $256 million. Wojcicki reop